Medtide Inc.
Research Medtide Inc. (3880.HK) on Bullrun: market cap HKD 2.89B, P/E 15.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3880.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 2.89B
- P/E15.3
- Financial periodFY2025
- RevenueCNY 570.09M
- Revenue growth28.9%
- Net incomeCNY 217.37M
- Free cash flowCNY 137.75M
- Gross margin63.4%
Valuation Snapshot
latest market cap is HKD 2.89B; P/E is 15.3.
Peer valuation comparison
Latest P/E is 15.34x versus a Healthcare sector median of 21.69x (29.3% below).
Latest P/E is 15.34x versus a China median of 16.26x (5.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 570.09M | CNY 217.37M | CNY 137.75M | 63.4% | 1.63 | CNY 887.86M | CNY 30.75M | CNY 1.58B |
| FY2024 | CNY 442.23M | CNY 59.17M | CNY 98.06M | 56.5% | 0.47 | CNY 387.62M | CNY 41.14M | CNY 318.75M |
| FY2023 | CNY 336.77M | CNY 48.91M | CNY 32.68M | 53.5% | 0.34 | CNY 531.45M | CNY 322.85M | CNY 253.88M |
| FY2022 | CNY 350.84M | CNY 53.98M | CNY 42.60M | 57.3% | 0.43 | CNY 279.48M | CNY 325.29M | CNY 202.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 2.89B | 15.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Medtide Inc.
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medtide Inc.'s market cap?
Medtide Inc.'s market capitalization is HKD 2.89B.
What is Medtide Inc.'s P/E ratio?
Medtide Inc.'s price-to-earnings (P/E) ratio is 15.3.
What does Medtide Inc. do?
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening.